Skip to main content

The Therapeutic Pipeline: Future Treatments and Precision Medicine

In brief

Three rare lung diseases now have treatments tied to their biology

A review finds disease-specific therapies advancing for acid sphingomyelinase deficiency, pulmonary alveolar proteinosis, and pulmonary Langerhans cell histiocytosis: enzyme replacement for the first, inhaled GM-CSF for the second, and BRAF or MEK inhibitors for patients with relevant mutations in the third. Some approaches remain under study, and whether newer diagnostics and treatments improve long-term outcomes is still unknown.

Journal
Seminars in respiratory and critical care medicine (Q1)
Published
13 November 2026
Study design
Narrative review / expert opinion
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Giovanni Franco, Giulia Peri, Alessia Ugonino-Gralino, Isabella Galbardi, Umberto Zanini, Paola Faverio, et al.
PMID
43025460
DOI
10.1055/a-3004-0630

Why clinicians should know about it

  • Picked for Genetics (clinical) (top studies of the week, 15 November 2026): Rare disease enzyme replacement and genotype-targeted therapies

Abstract

OBJECTIVE: rare interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by various pathogenic mechanisms, clinical presentations, prognoses, and therapeutic challenges. Among these, acid sphingomyelinase deficiency (ASMD), pulmonary alveolar proteinosis (PAP), and pulmonary Langerhans cell histiocytosis (PLCH) exemplify rare pulmonary diseases driven by distinct biological mechanisms, including lysosomal dysfunction, impaired surfactant homeostasis, and activation of the mitogen-activated protein kinases (MAPK) pathways. Recent advancements in molecular biology, genomics, and translational research boosted the development of precision medicine strategies and disease-specific therapies for these conditions. STUDY DESIGN: this narrative review was conducted in accordance with the SANRA guidelines. A thorough literature search of the PubMed/MEDLINE, Embase, and Scopus databases was performed from January 2000 to June 2026. RESULTS: significant progress has been made in treating all three diseases. In ASMD, enzyme replacement therapy with olipudase alfa has greatly improved visceral and lung symptoms, while research in gene therapy, gene editing, and metabolic treatments is ongoing. For PAP, inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) is now the primary disease-specific treatment, now supported by phase III trial evidence for inhaled molgramostim, complemented by potential therapies such as immunomodulation, macrophage transplantation, and gene-based strategies. In PLCH, the discovery of recurrent MAPK pathway variants has supported the use of genotype-targeted treatments with BRAF and MEK inhibitors. Under these conditions, advances in molecular diagnostics, circulating biomarkers, quantitative HRCT, radiomics, and artificial intelligence (AI) are poised to enhance diagnosis, patient stratification, prognosis, and treatment decisions. CONCLUSIONS: ASMD, PAP and PLCH are entering into an era of precision medicine, in which disease-specific molecular mechanisms play an increasing role in guiding diagnosis and treatment. Ongoing integration of genomics, biomarkers, advanced imaging, AI, and targeted therapies could revolutionise the management of conditions such as ASMD, PAP, and PLCH, leading to better long-term patient outcomes.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.